Iofina plc
("Iofina" or the "Company")
(LSE AIM: IOF)
Results of AGM
Iofina plc, manufacturers of specialty chemical products and specialists in the exploration and production of iodine, held its 2023 Annual General Meeting ("AGM") earlier today.
All resolutions proposed at the AGM, with the exception of resolution 6 (a special resolution for the disapplication of pre-emption rights), as set out in the Notice of Meeting dated 9 May 2023, were duly passed. The Company recognises that a meaningful proportion of votes were cast against resolution 6. Although the resolution was in line with the Company's historic AGM share authorities (all of which have been previously passed), the Board takes seriously its responsibilities to maintain a healthy dialogue with shareholders and will engage with the relevant shareholders to better understand their views.
The full text of the resolutions considered at the AGM are contained in the Notice of AGM which is available on the Company's website at www.iofina.com.
The table below shows the proxy position of all resolutions:
| RESOLUTIONS | FOR (and including at discretion) | AGAINST
| WITHHELD
| ||
|
Total votes cast: 57,380,461
| No. of votes | % | No. of votes | % | No. of votes |
| Resolution 1 | 57,379,717 | 99.99% | 0 | 0% | 744 |
| Resolution 2 To reappoint Malcolm Lewin as a director | 57,254,703 | 99.78% | 95,758 | 0.17% | 30,000 |
| Resolution 3 To reappoint Mary Fallin Christensen as a director | 57,344,961 | 99.93% | 5,500 | 0.01% | 30,000 |
| Resolution 4 To reappoint UHY Hacker Young LLP as auditors of the Company and to authorise the directors to determine their remuneration | 57,290,088 | 99.84% | 90,373 | 0.16% | 0 |
| Resolution 5 Pursuant to section 551 of the Companies Act 2006 (the "Act"), to unconditionally authorise the Directors to issue shares in the Company | 57,336,033 | 99.92% | 35,811 | 0.06% | 8,617 |
| Resolution 6 Disapplication of pre-emption rights. Pursuant to section 570 of the Act, and subject to resolution 5 being passed, to empower Directors to allot shares in the Company without first offering them to existing shareholders on a pro-rata basis | 36,498,805 | 63.61% | 20,881,656 | 36.39% | 8,617 |
| Resolution 7 Pursuant to section 701 of the Act, to unconditionally authorise the Company to make market purchases of ordinary shares in the capital of the Company (representing up to 10% of the issued share capital) | 57,325,458 | 99.90% | 37,873 | 0.07% | 17,130 |
Enquiries:
Dr. Tom Becker
CEO & President
Iofina plc
Tel: +44 (0)20 3006 3135
Nomad & Broker:
Henry Fitzgerald-O'Connor/Patrick Dolaghan/Andrew Potts
Canaccord Genuity Limited
Tel: +44 (0)20 7523 8000
Financial Adviser:
Kingsley Wilson
Chrystal Capital Partners LLP
Tel: +44 (0)20 7850 4761
Media Contact:
Charles Goodwin/Shivantha Thambirajah/Jazmine Clemens
Yellow Jersey PR Limited
Tel: +44 (0)7747 788 221/+44 (0)7983 521 488
About Iofina:
Iofina plc (AIM:IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.
LEI: 213800QDMFYVRJYYTQ84
ISIN: GB00B2QL5C79
Iofina Resources
Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.
Iofina Chemical
Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical will be celebrating its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
